Karolinska Development's portfolio company Umecrine
STOCKHOLM, SWEDEN – August 10, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the Board of Directors of the portfolio...
Source: globenewswire.com
📰 Johan Dighed News
Page 3 - Johan Dighed News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Johan Dighed. Real-time updates on events, politics, business and more.
Karolinska Development AB (publ): Karolinska Development's portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference
STOCKHOLM, Sweden, June 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Svenska Vaccinfabriken has presented results from a preclinical study indicating
Karolinska Institutet Johan Dighed Svenska Vaccinfabriken Viktor Drvota Karolinska Development Ab Nasdaq Stockholm Karolinska Development
Source: finanznachrichten.de
Karolinska Development's portfolio company Svenska
STOCKHOLM, Sweden, June 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Svenska Vaccinfabriken has...
Karolinska Institutet Johan Dighed Svenska Vaccinfabriken Viktor Drvota Karolinska Development Ab Nasdaq Stockholm Karolinska Development
Source: globenewswire.com
Karolinska Development's portfolio company Promimic
STOCKHOLM, Sweden, June 23, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic today presented...
Karolinska Institutet Johan Dighed Viktor Drvota European Technology Platform On Nanomedicine Chalmers University Of Technology Karolinska Development Ab Nasdaq Stockholm
Source: globenewswire.com
Investegate |Karolinska Development AB (pub Announcements | Karolinska Development AB (pub: Karolinska Development's portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants
Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants
Karolinska Institutet Johan Dighed Viktor Drvota European Technology Platform On Nanomedicine Chalmers University Of Technology Karolinska Development Ab Nasdaq Stockholm
Source: investegate.co.uk
Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants
STOCKHOLM, Sweden, June 23, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic today presented preclinical results tshowing that the company's HAnano
Karolinska Institutet Johan Dighed Viktor Drvota European Technology Platform On Nanomedicine Chalmers University Of Technology Karolinska Development Ab Nasdaq Stockholm
Source: finanznachrichten.de
Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals
STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology
Karolinska Institutet Johan Dighed Viktor Drvota Kd Aprea Atrin Atrin Pharmaceuticals Inc Karolinska Development Ab Nasdaq Stockholm
Source: finanznachrichten.de
Karolinska Development's portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients
STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of the company’s lead compound BSG005, targeting... | May 2, 2022
Karolinska Institutet Johan Dighed Viktor Drvota Eu Press Karolinska Development Ab Nasdaq Stockholm Karolinska Development
Source: marketscreener.com
Investegate |Karolinska Development AB (pub Announcements | Karolinska Development AB (pub: Karolinska Development's portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients
Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients
Karolinska Institutet Johan Dighed Viktor Drvota Karolinska Development Ab Nasdaq Stockholm Karolinska Development Nasdaq Stockholm
Source: investegate.co.uk
Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients
STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of the company's lead compound BSG005
Karolinska Institutet Johan Dighed Viktor Drvota Karolinska Development Ab Nasdaq Stockholm Karolinska Development Nasdaq Stockholm
Source: finanznachrichten.de